Patterns of Self-reported Diarrhea in Patients with Cancer Receiving Chemotherapy

Overview

Journal Support Care Cancer

Date 2025 Feb 5

PMID 39909912

Authors

Natalya Alekhina

Bob Wong

Katherine Sward

Kathi H Mooney

Affiliations

Soon will be listed here.

Abstract

Purpose: Diarrhea is prevalent in individuals with cancer undergoing chemotherapy and negatively affects their outcomes, treatment adherence, and survival. With the majority of patients receiving chemotherapy in an outpatient setting, treatment-related toxicities, including diarrhea, are experienced while at home, and, therefore, their prevalence, frequency, and associated distress remain largely uncaptured. This study aimed to assess the prevalence and severity of patient-reported diarrhea and the relationship between diarrhea severity and its associated distress.

Methods: We performed a secondary analysis of diarrhea severity and associated distress ratings (1-10) reported over the course of chemotherapy by individuals with various types and stages of malignancies. Symptoms were assessed daily through an automated telephone system.

Results: Out of 345 participants, 217 (62.90%) reported at least one episode of diarrhea. Of the reported diarrhea occurrences, 60.39% were classified as mild (1-3), 34.62% as moderate (4-7), and 4.99% as severe (8-10). The mean duration of mild, moderate, and severe diarrhea was 3.57, 4.84, and 1.43 days, respectively. Of all diarrhea episodes, 97.40% were reported between cycles 1 and 8, with cycle 1 having the greatest number of reported episodes. Out of these, cycle 5 had the highest average diarrhea severity (4.02) and cycle 8 the lowest (2.98). The average number of diarrhea reports per patient was 4.94 for participants in mild symptom group, 3.98 in moderate, and 1.78 in severe. A simple linear regression revealed a significant beta of 0.91 (p < 0.001) between diarrhea severity and the associated distress score.

Conclusions: Diarrhea affected over 60% of study participants. Its severity was highly correlated with patient-reported distress. Clinicians need to be aware that diarrhea can significantly disrupt patients' wellbeing and make it a priority of patient education and post-treatment assessment.

References

Sakumura M, Ando T, Hosokawa A, Nakajima T, Motoo I, Mihara H . Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea. BMC Gastroenterol. 2020; 20(1):355. PMC: 7590606. DOI: 10.1186/s12876-020-01507-5. View

Retornaz F, Guillem O, Rousseau F, Morvan F, Rinaldi Y, Nahon S . Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study. Oncologist. 2019; 25(1):e85-e93. PMC: 6964155. DOI: 10.1634/theoncologist.2019-0241. View

Lu D, Yan J, Liu F, Ding P, Chen B, Lu Y . Probiotics in preventing and treating chemotherapy-induced diarrhea: a meta-analysis. Asia Pac J Clin Nutr. 2019; 28(4):701-710. DOI: 10.6133/apjcn.201912_28(4).0005. View

Wang J, Feng W, Zhang S, Chen L, Tang F, Sheng Y . Gut microbial modulation in the treatment of chemotherapy-induced diarrhea with Shenzhu Capsule. BMC Complement Altern Med. 2019; 19(1):126. PMC: 6560905. DOI: 10.1186/s12906-019-2548-y. View

Fei Z, Lijuan Y, Xi Y, Wei W, Jing Z, Miao D . Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer. Gut Pathog. 2019; 11:18. PMC: 6489188. DOI: 10.1186/s13099-019-0299-4. View

Keefe D, Elting L, Nguyen H, Grunberg S, Aprile G, Bonaventura A . Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemother Pharmacol. 2014; 74(4):675-80. DOI: 10.1007/s00280-014-2526-5. View

Kee B, Morris J, Slack R, Crocenzi T, Wong L, Esparaz B . A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer. 2014; 23(3):661-70. DOI: 10.1007/s00520-014-2402-1. View

Diaz R, Kober K, Viele C, Cooper B, Paul S, Hammer M . Distinct diarrhea profiles during outpatient chemotherapy. Support Care Cancer. 2020; 29(5):2363-2373. DOI: 10.1007/s00520-020-05753-x. View

Bines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A . Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br J Cancer. 2021; 125(1):38-47. PMC: 8257679. DOI: 10.1038/s41416-021-01323-y. View

10.

Jensen N, Potter R, Kirchheiner K, Fokdal L, Lindegaard J, Kirisits C . Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018; 127(3):431-439. DOI: 10.1016/j.radonc.2018.05.016. View

11.

Reijtenbagh D, Godart J, Mens J, Heijkoop S, Heemsbergen W, Hoogeman M . Patient-reported acute GI symptoms in locally advanced cervical cancer patients correlate with rectal dose. Radiother Oncol. 2020; 148:38-43. DOI: 10.1016/j.radonc.2020.03.035. View

12.

Mooney K, Beck S, Wong B, Dunson W, Wujcik D, Whisenant M . Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med. 2017; 6(3):537-546. PMC: 5345623. DOI: 10.1002/cam4.1002. View

13.

Pearman T, Beaumont J, Mroczek D, OConnor M, Cella D . Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer. 2017; 124(5):991-997. PMC: 5892190. DOI: 10.1002/cncr.31133. View

14.

Griffiths P, Peipert J, Leith A, Rider A, Morgan L, Cella D . Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Support Care Cancer. 2022; 30(4):3613-3623. PMC: 8857159. DOI: 10.1007/s00520-022-06802-3. View

15.

Kim H, Jung S . Comparative evaluations of single-item pain-intensity measures in cancer patients: Numeric rating scale vs. verbal rating scale. J Clin Nurs. 2020; 29(15-16):2945-2952. DOI: 10.1111/jocn.15341. View

16.

Tarricone R, Abu Koush D, Nyanzi-Wakholi B, Medina-Lara A . A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. Crit Rev Oncol Hematol. 2016; 99:37-48. DOI: 10.1016/j.critrevonc.2015.12.012. View